×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:ATHA

Athira Pharma Insider Trading & Ownership

$3.43
+0.21 (+6.52%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.18
$3.51
50-Day Range
$2.74
$10.66
52-Week Range
$2.53
$16.65
Volume
1.43 million shs
Average Volume
2.10 million shs
Market Capitalization
$129.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.60

Athira Pharma (NASDAQ:ATHA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
14.90%
Number Of
Insiders Buying
(Last 12 Months)
3
Amount Of
Insider Buying
(Last 12 Months)
$940,980.00
Number Of
Insiders Selling
(Last 12 Months)
3
Amount Of
Insider Selling
(Last 12 Months)
$39,723.23

ATHA Insider Buying and Selling by Quarter

Get ATHA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Athira Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Athira Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2022Perceptive Advisors LlcDirectorBuy270,000$2.99$807,300.003,695,916  
6/28/2022Hans MoebiusInsiderBuy10,000$2.88$28,800.0052,955  
6/23/2022Mark James LittonCEOSell7,960$2.69$21,412.40128,555  
6/23/2022Mark WorthingtonGeneral CounselSell2,614$2.69$7,031.6619,097  
6/23/2022Rachel LeningtonCOOSell4,193$2.69$11,279.175,807  
3/31/2022Kelly A RomanoDirectorBuy8,000$13.11$104,880.00  
1/25/2021Perceptive Advisors LlcDirectorBuy311,111$22.50$6,999,997.50  
9/22/2020Joseph EdelmanDirectorBuy1,058,824$17.00$18,000,008.00
(Data available from 1/1/2013 forward)












Athira Pharma Insider Trading - Frequently Asked Questions

Who is on Athira Pharma's Insider Roster?

The list of insiders at Athira Pharma includes Hans Moebius, Joseph Edelman, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc, and Rachel Lenington. Learn more on insiders at ATHA.

What percentage of Athira Pharma stock is owned by insiders?

14.90% of Athira Pharma stock is owned by insiders. Learn more on ATHA's insider holdings.

Which Athira Pharma insiders have been buying company stock?

The following insiders have purchased Athira Pharma stock in the last 24 months: Hans Moebius ($28,800.00), Joseph Edelman ($18,000,008.00), Kelly A Romano ($104,880.00), and Perceptive Advisors Llc ($7,807,297.50).

How much insider buying is happening at Athira Pharma?

Insiders have purchased a total of 1,657,935 Athira Pharma shares in the last 24 months for a total of $25,940,985.50 bought.

Which Athira Pharma insiders have been selling company stock?

The following insiders have sold Athira Pharma stock in the last 24 months: Mark James Litton ($21,412.40), Mark Worthington ($7,031.66), and Rachel Lenington ($11,279.17).

How much insider selling is happening at Athira Pharma?

Insiders have sold a total of 14,767 Athira Pharma shares in the last 24 months for a total of $39,723.23 sold.

This page (NASDAQ:ATHA) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.